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Background: This paper introduces a tool for streamlining data integration in rehabilita-
tion science, the Centralized Open-Access Rehabilitation database for Stroke (SCOAR), 
which allows researchers to quickly visualize relationships among variables, efficiently 
share data, generate hypotheses, and enhance clinical trial design.
Methods: Bibliographic databases were searched according to inclusion criteria leaving 
2,892 titles that were further screened to 514 manuscripts to be screened by full text, 
leaving 215 randomized controlled trials (RCTs) in the database (489 independent groups 
representing 12,847 patients). Demographic, methodological, and statistical data were 
extracted by independent coders and entered into SCOAR.
results: Trial data came from 114 locations in 27 different countries and represented 
patients with a wide range of ages, 62  year [41; 85] [shown as median (range)] and 
at various stages of recovery following their stroke, 141  days [1; 3372]. There was 
considerable variation in the dose of therapy that patients received, 20 h [0; 221], over 
interventions of different durations, 28 days [10; 365]. There was also a lack of common 
data elements (CDEs) across trials, but this lack of CDEs was most pronounced for 
baseline assessments of patient impairment and severity of stroke.
conclusion: Data integration across hundreds of RCTs allows clinicians and researchers 
to quickly visualize data from the history of the field and lays the foundation for making 
SCOAR a living database to which researchers can upload new data as trial results are 
published. SCOAR is a useful tool for clinicians and researchers that will facilitate data 
visualization, data sharing, the finding of relevant past studies, and the design of clinical 
trials by enabling more accurate and comprehensive power analyses. Furthermore, 
these data speak to the need for CDEs specific to stroke rehabilitation in randomized 
controlled trials.
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inTrODUcTiOn
The information architecture in rehabilitation science is poor 
(1). For example, randomized controlled trials (RCTs) are the 
basic “unit” of information that guide clinical practice. Yet when 
clinicians and scientists want to ask a very basic question of these 
data, they are published: (1) across a wide spectrum of journals 
and formats that often have limited access (e.g., payment required 
for access); (2) embedded potentially in text, tables, figures, or 
even supplemental materials; and (3) with very few common data 
elements (CDEs) reported across studies (2, 3). Thus, despite the 
tremendous time and financial burdens associated with even a 
single RCT, the resultant data lack a consistent structure. This 
lack of structure is an unnecessary barrier to integration in 
future scientific and clinical practice. Efforts to streamline data 
integration should increase the transparency and visibility of 
comprehensive bodies of evidence, rather than a single study, 
to better inform clinically relevant questions such as, “How do 
therapy outcomes change with increased time in therapy?” or 
“How variable are outcomes, historically, for specific parameters 
of therapy?”
We now introduce one such tool for streamlining data inte-
gration: the Centralized Open-Access Rehabilitation database for 
Stroke (SCOAR). In short, SCOAR is a central repository for sum-
mary statistics from RCTs. SCOAR currently contains data from 
a systematic review and extraction of papers from 1981 to early 
2014 (described in detail below), but the goal of SCOAR is much 
bigger: to create a “living” database where new data can be added 
as clinical trials are completed. Imposing such an architecture (4) 
on clinical trial data would allow basic and clinical scientists to 
(1) quickly and easily visualize relationships among variables, (2) 
efficiently share data, (3) generate hypotheses based on notice-
able patterns or even “gaps” in the current data, (4) search the 
current literature from the data up (rather than key-terms down), 
and (5) improve clinical trial design through more accurate and 
comprehensive power analyses.
Generally speaking, the goal of SCOAR is to improve the 
design of future clinical trials by giving researchers fast and 
easy access to the historical range of effect-sizes, based on 
thousands of stroke patients who received therapies of different 
types, different doses, at different times, and were measured on 
different outcomes. From our perspective, the effort associated 
with the design, implementation, and dissemination of rand-
omized clinical trials deserves an information architecture that 
supports and increases their visibility. In the current paper, we 
(1) explain the systematic search and data extraction that led to 
the creation of SCOAR; (2) present summary statistics for the 
major variables in SCOAR, including the geographical reach, 
to understand how SCOAR data represent research in stroke 
rehabilitation; and (3) based on the lack of CDEs we find across 
many variables, we argue for a consistent set of CDEs in reha-
bilitation trials (CDEs to describe participants, methodology, 
and outcomes). SCOAR lays the foundation for an information 
architecture that captures some of the complex and multivariate 
nature of neurorehabilitation. Most importantly, this informa-
tion architecture is scalable, making it easy to add new data as 
new trials are published.
MaTerials anD MeThODs
systematic review
A systematic search was undertaken in May 2014 (full details in 
PROSPERO 2014:CRD42014009010) using the following data-
bases: MEDLINE, EMBASE, Cochrane CENTRAL, Cochrane-
CDSR, and CINAHL. Outside references were also incorporated 
from previous reviews (5, 6) (Figure 1). After removing duplicates, 
2,892 remaining titles and abstracts were screened by independ-
ent coders (two pairs of trained graduate students) based on the 
following inclusion/exclusion criteria (7):
Population
Human adults with stroke, >18  years of age, with a motor 
impairment as a result of stroke. Any etiology was included (e.g., 
ischemic, hemorrhagic, sub-arachnoid hemorrhage) provided 
that the study identified patients as having a stroke or cerebrovas-
cular vascular accident. Groups with mixed neurological impair-
ments (e.g., patients had either stroke or TBI) were excluded. (In 
the RCTs we found, the majority of groups were characterized 
as having first-ever unilateral strokes, without other neurological 
conditions, but these were not criteria for inclusion.)
Intervention
Any physical or occupational therapy interventions that required 
active movement on the part of the participant were included. 
RCTs that used stimulation techniques were allowed (e.g., FES, 
TMS, tDCS) if combined with active movement. Studies with 
strictly pharmaceutical interventions (e.g., to treat spasticity) 
were excluded.
Control
All studies had to be RCTs and studies were required to explicitly 
state random assignment to groups. The condition nominally 
identified as “control” by the authors was coded as control, or 
if a group received “conventional care,” “routine therapy,” or 
“standard care” without being specifically named as control, it was 
assumed that this was the control condition. All other conditions 
were labeled as “experimental.”
Outcome
Only empirically validated assessments of impairment or func-
tional motor capacity (i.e., activity limitations) administered by 
the clinician were taken as outcomes (e.g., no self-report meas-
ures, no neuro-imaging measures, no study-specific kinematic/
kinetic measures). Note that studies could include these other 
types of measures, but only measures of impairment or function 
were extracted for inclusion in the database at this time.
If there was disagreement between the coders, the first 
author (Keith R. Lohse) provided a tie-breaking vote on inclu-
sion or led discussion until agreement was reached. The same 
PICO inclusion/exclusion criteria were also applied to the full 
text review. During the full text review, the authors systemati-
cally extracted data from the manuscripts (described below in 
Section “Data Extraction”). During the extraction, concerns 
emerged regarding how to consider statistically related 
data within SCOAR. In other words, SCOAR is designed to 
FigUre 1 | PrisMa Flow diagram showing the manuscript screening process. At the eligibility assessment, manuscripts were excluded if the population 
was not stroke, there was no random assignment to at least two different groups, if the intervention did not meet our population, intervention, control, and outcome 
criteria, if the outcomes were not a clinical measure of function/impairment, if no full text of manuscript was available (e.g., restricted access or the text only existed 
in abstract form), if the data in the manuscript came from a larger study/reanalysis of a study that was already in the database, if the manuscript was a review, 
commentary, or a trial protocol (rather than a trial itself), or if it was not clear how the study related to an existing study in the database (i.e., possibly the same 
patients being analyzed twice; coded as “other”).
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longitudinally track groups over time (viz., from baseline 
assessment, to terminal assessment, to the last long-term 
follow-up) and, therefore, studies with long-term follow-up 
data, subsets of data, or re-analyzed data published in separate 
manuscripts presented a unique challenge. To maintain inde-
pendence of the data for statistical analysis, any given group 
of patients should only appear in the SCOAR database once. 
Thus, subsets and re-analyses were excluded (n = 8) or if the 
relationship between manuscripts was unclear (n = 5), those 
studies were excluded as well. However, if a paper published a 
long-term follow-up or reported usable outcome measures in 
a separate manuscript (n = 8), then these data were grouped 
together in the SCOAR database [e.g., Ref. (8–11)], such that 
independence between groups is maintained. As shown in 
Figure  1, there were a number of studies for which the full 
text could not be obtained (n = 49), or even if the full text was 
available, there was no available English translation (n =  9). 
(At present, no effort has been made to translate these non-
English texts, but with adequate translation, the data from 
these studies may be eligible for inclusion following review.) 
In total, SCOAR has summary statistics from 12,847 patients 
in 489 independent groups (as of 2016-03-31).
Data extraction
Separate from the pairs of graduate students who screened by title 
and abstract, three authors (Keith R. Lohse, Sydney Y. Schaefer, 
Adam C. Raikes) extracted data by hand from electronic copies 
of manuscripts using a standardized data extraction form. These 
extracted values were then entered by hand into a spreadsheet. 
Discrepancies between extractors were discussed until consensus 
was reached. A copy of the data extraction form is listed in Data 
Sheet S1 in Supplementary Material and an explanation of all 
current SCOAR variables is included in the data dictionary, Data 
Sheet S2 in Supplementary Material.
One author (Keith R. Lohse) extracted outcome data for 
either the primary outcome or the first usable outcome, when 
no primary outcome was stated or the primary outcome was not 
usable. As per the PICO criteria, a usable outcome measure was 
defined as an assessment given by a therapist that was a clinical 
measure of motor impairment and/or function. Two authors 
( Sydney Y. Schaefer, Adam C. Raikes) also reviewed all of the 
articles to extract all additional data related to the Fugl–Meyer 
Assessment (FMA, upper-extremity portion, a measure of upper 
limb impairment) and gait speed (including the 10-m walk test, 
or variations thereof, a measure of walking function). This second 
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set of outcomes was extracted regardless of whether the FMA 
or gait speed measure was stated as a primary outcome. FMA 
and gait speed measures were chosen for this second extraction 
because they were the most commonly reported measures for 
those two domains in previous work (12).
In extracting these data, the relevant outcome data were 
often clearly presented. For instance, baseline means and SDs 
were consistently reported in the text (i.e., the pre-intervention 
assessment, reported in 93 and 83% of cases), whereas terminal 
means (i.e., the most immediate post-intervention assessment; 
calculable for 93% of cases) sometimes had to be calculated 
by the data extractors from reported change scores (12% of 
calculable cases). Additionally, terminal SDs (calculable for 
72% of cases) were sometimes estimated by the data extractors 
from figures or reported confidence intervals (3% of calculable 
cases).
Other data were often not reported in the text and, there-
fore, had to be estimated by the data extractors. For instance, 
the time scheduled for therapy was typically estimated from 
written descriptions (e.g., “1  h per day, 5  days per week for 
4 weeks” = 20 h of scheduled therapy). An estimate of the time 
scheduled for therapy was calculable in 74% of cases. Although 
some studies reported repetitions of movements (13, 14) or 
active time in therapy (15, 16), the most common metric was 
the time scheduled for therapy. Although time scheduled for 
therapy is likely to be a poor indicator of the actual amount of 
therapy received (17), it is positively correlated with the amount 
of therapy received and was the most common metric reported 
across trials. Constraint-induced movement therapies (18, 
19) or other “forced-use” therapies (20) were problematic for 
estimating the time scheduled for therapy because they often 
do not specify the amount of time actually spent in constraint 
or forced-use. In line with previous work (6), we calculated 
time under constraint in three different ways: (1) counting 
100% of constraint time as time in therapy, (2) counting 50% 
of constraint time as time in therapy, and (3) counting 0% of 
constraint time as time in therapy. The 50% time calculation is 
preferred because it has the most plausible assumptions (i.e., 
some, but not all, of constraint time is spent using the affected 
extremity), but all three calculations are available to researchers 
in the database. We further note that some constraint studies 
reported constraint for a “percentage of waking hours,” and 
these percentages were converted to hours based on 16 waking 
hours per day.
estimation of Within-group effect size
Compared to effect-size calculations in other rehabilitation meta-
analyses (5, 6), the default effect-size in SCOAR represents the 
change within groups over time rather than a difference between 
groups at a specific time point. Calculating a standardized 
effect-size for within-group change is important, because these 
effect-sizes allow for the greatest flexibility in integrating changes 
across studies using the most data [i.e., each group’s improvement 
(or decrement) is normalized to their baseline at the beginning 
of the intervention]. Calculation of these within-group changes 
creates some unique challenges for meta-analysis (see below), but 
all effect-size calculations were for a Cohen’s d as described in 
Borenstein et al. (21).
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where spooled is the between-person SD pooled between the two 
different time points to create a single estimate of the between-
person variance.
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2and s  refer to the variance at the baseline and the 
terminal assessment, respectively. In 28% of the total cases, the 
variance was not estimable at the terminal assessment. However, 
in 16% of the total cases the baseline SD was available and used 
in the calculation of d when the terminal SD was not available. In 
fewer cases (1% of total cases), the variance at baseline was zero 
(e.g., all participants had a Functional Ambulation Category of 
zero due to a floor effect in the outcome measure). In those cases, 
the terminal SD was used in the calculation of d.
Finally, given the wide range of the effect-sizes and sample 
sizes we observed in the data, we transformed these effect-sizes 
from Cohen’s d to Hedges’ g. Cohen’s d is biased to overestimate 
the underlying effect-size in small samples whereas Hedges’ g is a 
more conservative and unbiased calculation of the effect-size in 
which the d value is reduced proportional to the sample size (21). 
Subtraction in the effect-size calculations was arranged such that 
positive values in SCOAR always reflect improvement relative to 
baseline.
Although the default effect-sizes in SCOAR represent the 
normalized improvement within a group over time, we should 
point out that SCOAR also contains the sample size, mean, and 
SD for all groups at the baseline, terminal, and follow-up assess-
ment (if applicable). Having these descriptive statistics for each 
group at each time point allows researchers to readily calculate 
between-group effect sizes if those effects are more relevant to 
their research question. Thus, by extracting the sample size, 
mean, and SD at each time point, SCOAR allows researchers to 
calculate outcomes in three different ways: (1) a standardized 
effect-size showing change within a group over time (the default 
SCOAR effect-size), (2) a standardized effect-size showing the 
difference between groups at a single point in time, or (3) the 
original “raw” units of the outcome measure. Although using 
original units precludes combining different outcomes into a 
single analysis, this is a sensible option when restricting out-
comes to a single type (i.e., measures of gait speed can all be 
expressed in terms of meters per second, so there is no need to 
normalize).
estimation of the correlation between 
Time Points and effect-size Variance
In order to conduct quantitative meta-analyses with these data, we 
also need to calculate the variance of the individual effect-sizes. 
For statistically dependent “within-subject” data, the correlation 
TaBle 1 | Demographic statistics for the studies included in scOar.
Variable Mean (sD) Median (iQr) Min; Max groups with  
missing values
Mean patient age (years) 62.6 (6.7) 62.4 (57.3; 67.3) 41.30; 85.20 12
Mean days post stroke (days) 509 (652) 141 (31; 840) 1; 3,372 22
Duration of intervention (days) 45 (39) 28 (28; 42) 10; 365 20
Estimated Time Scheduled for Therapy (h)
Max time calculation 34.2 (45.3) 20.0 (10.0; 36.1) 0.0; 280.0 129
50% time calculation 29.9 (31.6) 20.0 (10.0; 36.0) 0.0; 220.7 129
Min time calculation 25.5 (24.5) 20.0 (10.0; 32.0) 0.0; 220.7 129
Method for Tracking Dose of Therapy – N (% out of 489)
Hours scheduled 307 (63%)
Time in therapy 26 (5%)
Active time 37 (8%)
Repetitions 20 (4%)
Groups Reporting ITT Analysis 158 (32%)
N per Group at baseline calculation 26 (26) 18 (11; 31) 4; 165 0
N per group at terminal calculation 25 (25) 17 (10; 30) 4; 165 6
N per Group at follow-up calculation 29 (29) 19 (2; 34) 4; 165 215
Time from baseline to follow-up (days) 178 (137) 180 (88; 206) 31; 1,098 231
Coded as experimental groups 285 (58%)
Coded as control groups 204 (42%)
N per group refers to the number of participants whose data were used in the calculation of the mean and the SD at each time point, not necessarily the number of participants 
enrolled in/actively participating in the study at that time point (depending on the analytical method used by the authors). Time in days and N per group are rounded to the nearest 
integer. ITT = intention to treat.
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between time points, r, is required for an accurate estimation of 
effect-size variance, Vd (21).
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The correlation between baseline and terminal (or follow-
up) scores was never reported in any of the included RCTs. We 
were, however, able to estimate the correlation between baseline 
and terminal assessments from studies that provided either (A) 
individual patient data or (B) SDs of the baseline, terminal, and 
baseline-to-terminal change scores (21). In this subset of stud-
ies (13, 22–34), we observed that the median correlation was 
r = 0.87, IQR = (0.70, 0.93) and the minimum correlation was 
r = 0.28 between baseline and terminal assessments. As such, 
we calculated effect-size variance based on the conservative 
assumption that r = 0.5 for all studies (which generally creates 
larger estimates of variance in the data, widening our confidence 
intervals). This estimated correlation is, however, an easy value 
for researchers to manipulate within SCOAR and recalculate 
their own effect-size variances. Thus, the default effect-size 
variance in SCOAR is calculated based on r =  0.5, which we 
consider to be a conservative estimate, but researchers can easily 
recalculate effect-size variances by scaling this correlation up 
or down.
resUlTs
Descriptive statistics across the 489 independent groups of par-
ticipants currently in the database are listed in Table 1. The full 
database (as of 2016-03-31), the data dictionary, a full reference 
list all trials, and the Creative Commons license for SCOAR are 
available from https://github.com/keithlohse/SCOAR. (Note that 
SCOAR is licensed under a Creative Commons Attribution-
ShareAlike 4.0 International License by Keith R. Lohse.)
As shown in Table 1, the data in SCOAR are representative of 
a wide range of patients (in terms of day-post stroke and age) and 
different types of interventions (in terms of sample size, duration 
of the intervention, and dose of therapy given over the interven-
tion). An important point to note are the different methods used 
for tracking the dose of therapy patients received. Consistent with 
our previous work (6), the most common metric for tracking dose 
was the hours of scheduled therapy. The best measures of dose are 
the time actively spent doing therapy (19, 35) (which was more 
commonly reported in gait therapies) or the actual repetitions of 
therapy exercises (14, 36) (which was more commonly reported 
in trials using robotic assistive devices).
geographical Distribution of studies
As shown in Figure 2, trials in the SCOAR database come from 
a wide range of countries. The location of a trial was estimated 
based on the contact information for the corresponding author. 
Note that multiple studies may be represented by each dot (if 
trials were conducted at the same location), so we refer readers 
to the interactive version of this figure1 where they can see the 
number of trials, number of groups, and the references for each 
location. Overall, trials came from 114 locations in 27 different 
countries. From this wide range of trial locations, it does not 
appear that SCOAR is geographically biased relative to the larger 
population of stroke rehabilitation trials. The extent to which the 
population of trials might be biased, however, is an important 
1 http://tinyurl.com/SCOAR-regions 
TaBle 2 | Most common data elements for baseline measures in the 489 
independent groups included in scOar.
Measure number of groups 
with mean/median 
value reported
 number of groups  
with cut-off stated  
in i/e criteria only
not  
reported
MMSE  
(or modified) (37)
82 (17%) 70 (14%) 337 (69%)
Ashworth (or 
modified) (38)
63 (13%) 25 (5%) 401 (82%)
Barthel  
(or modified) (39)
68 (14%) 2 (<1%) 419 (86%)
FAC (40) 46 (9%) 10 (2%) 433 (89%)
FIM (41) 47 (10%) 2 (<1%) 440 (90%)
Brunnstrom  
stages (42)
24 (5%) 20 (4%) 445 (91%)
Motricity Index (43) 28 (6%) 7 (1%) 454 (93%)
NIHSS (44) 34 (7%) 0 (0%) 455 (93%)
Berg Balance  
Scale (45)
34 (7%) 0 (0%) 455 (93%)
I/E, inclusion/exclusion criteria, MMSE, Mini-Mental Status Exam, FAC, Functional 
Ambulation Category, FIM, Functional Independence Measure, NIHSS, National 
Institutes of Health Stroke Scale.
FigUre 2 | geographical distribution of studies in the scOar database based on the contact information for the corresponding author. Each dot 
represents one city in a given region, but there may be multiple studies from a single city (e.g., there are three different RCTs and six independent groups, from 
Chicago, IL, USA). An interactive version of this figure is also available from http://tinyurl.com/SCOAR-regions; generated using Tableau 9.0 (Tableau Software; 
Seattle, WA, USA).
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question. As seen in Figure 2, there is a dearth of trials for regions 
such as South America, Africa, central Asia, and eastern Europe.
common Data elements for Baseline 
assessment and initial severity
Across the 489 independent groups of participants, there was a 
wide range of data elements, but unfortunately there were rela-
tively few CDEs reported across the different studies. This lack 
of CDEs was especially pronounced for variables measuring the 
baseline severity of stroke or patient impairment. For example, 
data describing cognitive status with the Mini-Mental Status 
Exam (MMSE) were reported for only 152 groups in some form 
(31% of cases). A mean or median MMSE score was given for 82 
(17%) of these groups, whereas 70 (14%) of these groups only 
reported some cut-off/critical MMSE value in their inclusion/
exclusion criteria. The MMSE example was not unusual, however, 
and was actually the most common CDE for baseline assessment. 
For a list of the most common baseline assessments and their 
prevalence (see Table 2).
This lack of CDEs (or at least under-reporting of CDEs) is 
undoubtedly a major barrier to data integration and meta-analysis, 
especially for ostensibly common baseline assessments, such as 
the FIM or NIHSS. We should clarify that it is possible that authors 
were using these assessments/screening criteria in the actual trial, 
but they may not have been reporting these measures and we can 
only extract and analyze the descriptive statistics based on the 
published information. Indeed, many inclusion/exclusion criteria 
were vague, with authors often reporting “no excessive spasticity” 
(implying perhaps the Ashworth scale was used), “no cognitive/
communicative impairments” (implying the MMSE may have 
been used), or “no severe depression” (implying perhaps the Beck 
Depression Inventory or the Center for Epidemiological Studies 
FigUre 3 | The frequency of different outcome measures for the 
upper-extremity (ue, n = 212), lower-extremity (le, n = 443), and 
subscales of those two codes. Complex whole body assessments that 
did not fit into one of these two categories were unclassified (n = 144).
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depression scale were used). Without more complete reporting, 
we have no way of knowing which measures were collected and 
how participants were evaluated. This presents a major gap in 
stroke rehabilitation knowledge (1).
classification and Description  
of Therapy Types
An unexpected difficulty in the construction of the SCOAR 
database was in how to categorize/classify different therapeutic 
interventions. Ideally, researchers could use the SCOAR database 
to look at effect-sizes as a function of therapy-type or ask other 
meta-scientific questions about therapy types. Indeed, we were 
able to extract a short phrase or informative description of the 
therapy for almost all of the experimental groups (e.g., “CIMT,” 
“intensive progressive treadmill training”; these descriptions are 
listed under the “group_desc” variable in the SCOAR database), 
consistent with TIDieR Criteria (46, 47). For control groups, 
however, this proved much more difficult, with many descrip-
tions being simply “conventional physiotherapy,” “standard 
care,” or “routine care.” We are currently pursuing text-mining 
approaches to better quantify the nature of therapy provided in 
control-arms of trials. In the included RCTs, however, control 
groups were under-described compared to experimental groups 
(48). Looking strictly at the Methods sections of papers, for 
instance, control groups only had a mean (SD) of 155 (112) 
words and 0.82 (1.9) references dedicated to their description. 
Experimental groups, conversely, had 271 (159) words and 1.77 
(3.4) references dedicated to their description. Example control 
group descriptions are:
“All participants received standard rehabilitation, 
including 40 minutes each of physiotherapy and occu-
pational therapy, given once per day, five days per week 
for six weeks, by the rehabilitation team. [… sentence 
about experimental group omitted…] The control group 
had visits and discussions of 20 minutes at least three 
times per week instead.” (49)
“All participants received the site’s conventional inpa-
tient rehabilitation. They also performed a daily 10-m 
walk (or shorter distance walk until 10 m was feasible) 
as part of a physical therapy session.” (50)
“All participants received a duration-matched interven-
tion for 90 to 105 minutes/day, 5 days/week for 4 weeks. 
The CT group received an intensive therapist-admin-
istered control therapy matched in duration with the 
RT groups. Occupational therapy techniques used in 
the treatment protocols included neurodevelopmental 
treatment, muscle strengthening, fine-motor training, 
and functional task training.” (14)
Adequate descriptions of control therapies are critical, not 
only because the SCOAR database spans three decades and 
“routine” therapy has changed considerably over that period, but 
also because it is impossible to compare the efficacy of a treat-
ment across trials if the control groups to which the treatment is 
compared are very different. At the moment, the under-describing 
of control therapies allows for very different interventions to all 
be categorized as “standard care” in different trials.
classification and common Data 
elements in Outcome Measures
There is a very wide range of outcome measures in SCOAR 
(n = 78 discrete outcome names) (3). Despite this multiplicity, 
all of the SCOAR outcomes are measures of impairment and/or 
motor function. Thus, these outcomes could be analyzed together 
in order to get a broad view of motor recovery outcomes. We 
have, however, built in several default filters in SCOAR to help 
researchers group common outcomes more quickly. The first filter 
is the “outcome_extremity” variable in the database, which codes 
outcomes based on the involvement of the upper-extremity (ue) 
and lower-extremity (le). Variables that do not cleanly fit into one 
of these categories (e.g., the Barthel Index or other activities of 
daily living scales) are left blank. Within the ue and le outcomes, 
we further subdivide outcomes with a second-level filter. Second-
level filter codes for the upper-extremity in SCOAR include the 
Fugl–Meyer Assessment (fma), Action Research Arm Test (arat), 
and Wolf Motor Function Test (wmft). Second-level filter codes 
for the lower-extremity in SCOAR include measures of walking 
speed (including the 10-m walk test and variants thereof), walking 
endurance (including the 6 min walk test and variants thereof) 
and balance (which includes the Timed Up and Go Test and the 
Berg Balance Scale). The number of outcomes of each type is 
shown in Figure 3.
Naturally, some researchers may disagree with the filters/
groupings, we have created for the defaults in the SCOAR database. 
As such, outcomes are also coded without a filter, using the name 
of the outcomes from the original study (the “outcome_name” 
variable in the database). In many cases, this unfiltered option 
will be appealing because it offers the user the greatest control 
over what information to pool together. However, if the user does 
not care which subscale of the FMA is being used (e.g., the ue 
total subscale, the wrist-hand subscale, or the shoulder-elbow 
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subscale) then the second-level filter fma would be appropriate 
to use. Similarly, walking speed was measured in many different 
ways across the different studies. For example, walking speed 
was measured over 10, 8, or even 4.2 m, and at both self-selected 
velocity and maximal effort, but if the user is not concerned about 
such differences in these outcomes, then the second-level filter 
speed would be appropriate to use.
The wide variation in outcomes measures means that if a 
researcher wants to focus on a single outcome, it would greatly 
reduce the amount of data that can contribute to any single 
analysis. As with baseline CDEs, the reporting of so many differ-
ent outcome measures with so few common outcome measures 
imposes severe limitations on hypothesis generation and data 
exploration. From the SCOAR database, there is a strong argu-
ment for consistent CDEs describing participant demographics, 
study methodology, and clinical outcomes. Panels of experts 
would be required to determine exactly what these CDEs should 
be (e.g., What are the best UE/LE outcome measures with respect 
to their sensitivity and clinical application?). While the exact bat-
tery of CDEs needs to be determined, it is clear that creating a 
comprehensive set of rehabilitation specific CDEs would enable 
researchers to ask innovative questions of existing data, bringing 
the results of hundreds of trials to bear on clinically relevant top-
ics with unprecedented precision and statistical power.
Data-Driven searches and novel Filters
A major advantage of organizing trial data in a central repository 
is that it can complement traditional bibliographic databases, such 
as PubMed or EMBASE. Traditional bibliographic tools assist 
authors in finding data from the top-down. That is, researchers 
arrive at data via well-designed searches using key terms, author 
names, medical subject headings, etc. By contrast, data-driven 
searches allow authors to find resources from the bottom-up. That 
is, SCOAR allows researchers to plot the relationships between 
variables and then click on large, outlying, or otherwise interest-
ing data-points to obtain more information about that trial, such 
as patient demographics, type of intervention, and the reference 
for the published manuscript. For example, see http://tinyurl.
com/SCOAR-datasearch.
In addition to these data driven searches, SCOAR enables 
researchers to constrain their searches by filters that are not 
available in bibliographic databases. For instance, a researcher 
could filter SCOAR to find only those trials that have used the 
ARAT as an outcome, in patients < 70 years old, and with sample 
sizes greater than 30. [Indeed, there are currently two studies in 
SCOAR that meet these specific criteria (51, 52).] Having these 
key variables describing participant demographics, research 
methodology, and clinical outcomes in an easily searchable 
database makes SCOAR a very useful compliment to existing 
bibliographic databases.
DiscUssiOn
While SCOAR is a large step forward for data integration in stroke 
rehabilitation research, there are limitations associated with the 
database in its current form and limitations in using a database 
with “group-level” statistics more generally. One limitation is 
completeness; the data currently in SCOAR represent two waves 
of data extraction: the first wave extracted the first primary or 
secondary outcome measure that met our inclusion criteria while 
the second wave extracted any assessment based on the FMA or 
a measure of gait speed/endurance. This creates a representative, 
but not exhaustive extraction of all of the outcome measures 
used across the various studies. Currently, we are extracting the 
remaining outcomes from these RCTs, regardless of whether or 
not this outcome was primary or secondary. Once this third wave 
of data extraction is complete, SCOAR will contain all of the avail-
able summary statistics for any clinical measure of impairment or 
function used in these studies. We have also re-implemented our 
systematic search to update the database through 2016 and are 
in the process of extracting demographic, methodological, and 
statistical information from those studies.
Even as the evidence base in SCOAR expands, there is a 
major concern with the lack of CDEs in both outcome and 
baseline measures. From an information architecture perspective, 
reporting multiple outcomes per trial poses a unique problem. 
For instance, self-selected gait speed and maximal gait speed or 
various subscales of the FMA could all be reported in the same 
RCT. In SCOAR, this can be resolved by creating separate rows 
for each outcome, which is a relatively simple problem of scale. 
For the researcher, however, it is not always clear which measure 
is best or if one should average across multiple related measures, 
reflecting a more complicated problem of ontology (i.e., what 
are the fundamental constructs in rehabilitation and how do 
we measure them?) (53–55). This lack of CDEs is indicative of 
a larger problem for rehabilitation science as a field: researchers 
need to think critically about which measures to collect/analyze 
in order to reduce the risk of false positives (56–58) and (ideally) 
develop a set of common measures for key constructs (1, 2, 59) 
that would allow for greater data integration across trials.
Similarly, a major concern across trials was in the way that 
therapies were reported. For control therapies in particular, the 
descriptions of the control interventions were vague and under-
reported in comparison to experimental interventions. Control 
therapies had approximately half of the words dedicated to their 
description as experimental therapies. This lack of detail might 
be acceptable if control therapies had sufficient references to sup-
port them (e.g., references to standard operating procedures or 
other published guidelines). However, this does not seem to be 
the case, as control interventions had about half of the number 
of references in their descriptions compared to experimental 
interventions, and less than one reference on average. (It should 
be noted that these word/reference counts were based only on the 
text in the Methods sections of the original papers.)
For both control and experimental therapies, there is also a 
concern about how the dose of therapy is reported across trials. 
At the moment, the only consistently reported measure was time 
scheduled for therapy and we stress that this measure gives only 
a rough indication of the amount of physical practice actually 
performed during therapy. It would be preferable to develop a 
system where the type, intensity, and volume of physical prac-
tice could be tracked for individual patients and consistently 
FigUre 4 | schematic showing the transformation of data from an unstructured format (i.e., separate texts, tables, and figures, often behind 
paywalls) to a structured format (i.e., scOar database) and our long-term goal of making scOar accessible to researchers through the internet. 
This webpage would allow users to interact with the data (generating both statistical and graphical outputs) and allow researchers to upload new data (following a 
validation process) as new trials are published.
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reported across studies. The development of such a system would 
be a large undertaking, but if there was a consistent mechanism/
taxonomy for quantifying what exercises were done, at what 
intensity, and at what volume during therapy, this would help 
overcome problems with under-describing therapies. Such a 
taxonomy, if validated, would also improve our understanding 
of what the key “active-ingredients” actually are in physical and 
occupational therapy (60).
Another limitation of having a database of summary statistics, 
rather than individual patient data, is the “resolution” of the data 
available to researchers. Obviously this resolution would be finer 
if individual data were available for each patient in each trial (for 
example, see the Virtual International Stroke Trials Archive),2 
but having a database of individual patient data raises privacy 
concerns that limit open-access to the database and (potentially) 
the type of variables that can be included in the database (i.e., data 
that may jeopardize anonymity). Thus, SCOAR is ultimately more 
“share-able” than individual patient data and potentially easier to 
maintain.
Finally, as shown in Figure 4, the long-term goal of SCOAR is 
to create a “living” database where researchers can add new trials 
to the database through the internet. We are currently working to 
develop a website with a graphical user interface that would exist 
on top of SCOAR, allowing researchers to visualize relationships 
between different variables in the database and/or download 
the raw data from SCOAR so that they can work with it offline. 
2 http://www.vista.gla.ac.uk/ 
Furthermore, a major goal of this website is to allow researchers to 
upload new data as trials are published. By creating fillable forms 
that fit our data structure, we can make it very easy for researchers 
(e.g., the corresponding authors) to upload demographic infor-
mation about their participants, methodological data about their 
intervention, and statistical information about their outcomes. 
This uploading would be validated by one of the SCOAR study 
personnel working with the author to ensure the quality/accuracy 
of the new data before it is officially added to SCOAR.
cOnclUsiOn
The SCOAR database currently integrates demographic, method-
ological, and statistical data from 215 RCTs (representing 12,847 
patients) that allows researchers to quickly visualize relationships 
between variables in motor rehabilitation for adults with stroke. 
Integrating data from 30+ years of published studies is certainly 
not trivial, but establishing this information architecture makes 
it easy to scale the database as new trials are published. In our 
own research, we are using SCOAR to analyze how the dose 
and timing of therapy interact to affect therapy outcomes, and 
by combing data from SCOAR with text-mining approaches we 
are exploring what “conventional” or “standard” therapy actually 
means in the context of RCTs (48). The open-access nature of 
SCOAR will help researchers and clinicians to (1) visualize 
relationships among variables based on the history of the field, 
(2) efficiently share data between trials, (3) generate hypotheses 
by allowing for exploratory meta-analyses, (4) search the current 
literature by complimenting existing bibliographic databases, and 
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